Q1 EPS Forecast for X4 Pharmaceuticals Increased by Analyst

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Stock analysts at HC Wainwright raised their Q1 2025 EPS estimates for shares of X4 Pharmaceuticals in a report released on Thursday, March 27th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.02) per share for the quarter, up from their prior forecast of ($0.15). HC Wainwright has a “Buy” rating and a $1.50 price target on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.32) EPS, FY2026 earnings at ($0.23) EPS and FY2027 earnings at ($0.16) EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $1.43 million during the quarter, compared to analysts’ expectations of $1.07 million.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $3.00 price target on shares of X4 Pharmaceuticals in a report on Wednesday, March 26th.

X4 Pharmaceuticals Trading Down 7.8 %

Shares of XFOR stock opened at $0.25 on Monday. The company has a market capitalization of $43.42 million, a P/E ratio of -2.78 and a beta of 0.39. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. The business’s 50 day moving average is $0.43 and its two-hundred day moving average is $0.52. X4 Pharmaceuticals has a twelve month low of $0.24 and a twelve month high of $1.60.

Insider Activity at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 74,773 shares of the business’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Paula Ragan sold 76,473 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $34,412.85. Following the transaction, the chief executive officer now directly owns 1,087,386 shares in the company, valued at approximately $489,323.70. This trade represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 202,663 shares of company stock worth $91,198 over the last 90 days. Company insiders own 1.62% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cantor Fitzgerald L. P. purchased a new position in X4 Pharmaceuticals in the 4th quarter valued at approximately $30,000. Verition Fund Management LLC purchased a new position in shares of X4 Pharmaceuticals in the third quarter valued at $30,000. Atria Wealth Solutions Inc. acquired a new position in shares of X4 Pharmaceuticals during the 4th quarter worth $44,000. Wells Fargo & Company MN boosted its position in shares of X4 Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock worth $58,000 after buying an additional 26,763 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in X4 Pharmaceuticals by 20.3% in the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after acquiring an additional 22,485 shares during the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.